Vivo Opportunity Fund Holdings, L.P. → ArriVent BioPharma, Inc. AVBP

Stake: — Shares: — Class: Common Stock, $0.0001 Par Value per Share

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

4 transactions

4 buys · 0 sales · 0 awards/exercises

Issuer Cluster

2 13D/G filings on this issuer

1 other filing besides this one

Filer Track Record

4 filings by this filer

3 other filings in the data moat

Short Interest · settle 2026-09-30

DTC 11.25

8,451,472 shares short · -3.6% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $4.36M

Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-06-18	Parsey Merdad	director	Award	13,562	$31.74	$430K
2026-06-18	Peterson Kristine	director	Award	13,562	$31.74	$430K
2026-06-18	Hohneker John	director	Award	13,562	$31.74	$430K
2026-06-18	Nolet Chris	director	Award	13,562	$31.74	$430K

Other 13D/G Filings on ArriVent BioPharma, Inc.

Filed	Form	Filer	Stake	Shares
2026-10-08	SCHEDULE 13D/A	ORBIMED ADVISORS LLC	5.80%	2,875,962	view →

Other Filings by Vivo Opportunity Fund Holdings, L.P.

Filed	Form	Issuer	Stake	Shares
2026-07-08	SCHEDULE 13G	Achieve Life Sciences, Inc. ACHV	—	—	view →
2026-06-10	SCHEDULE 13D	InMed Pharmaceuticals Inc. INM	21.70%	718,444	view →
2023-10-11	SC	SOLENO THERAPEUTICS INC SLNO	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →